Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment
Metrics: PDF 2596 views | HTML 2409 views | ?
Masaki Kaibori1,*, Kazuko Sakai2,*, Morihiko Ishizaki1, Hideyuki Matsushima1, Marco A. De Velasco2, Kosuke Matsui1, Hiroya Iida1, Hiroaki Kitade1, A-Hon Kwon1, Hiroaki Nagano3, Hiroshi Wada3, Seiji Haji4, Tadashi Tsukamoto5, Akishige Kanazawa5, Yutaka Takeda6, Shigekazu Takemura7, Shoji Kubo7, Kazuto Nishio2
1Department of Surgery, Hirakata Hospital, Kansai Medical University, Hirakata, Osaka, 573-1010, Japan
2Department of Genome Biology, Kinki University Faculty of Medicine, Osakasayama, Osaka, 589-8511, Japan
3Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan
4Department of Surgery, Kinki University Faculty of Medicine, Osakasayama, Osaka, 589-8511, Japan
5Department of Hepato-Biliary-Pancreatic Surgery, Osaka City General Hospital, Miyakojima, Osaka, 534-0024, Japan
6Department of Surgery, Kansai Rosai Hospital, Amagasaki, Hyogo, 660-8511, Japan
7Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine, Osaka, 558-8585, Japan
*These authors have contributed equally to this work
Kazuto Nishio, email: email@example.com
Keywords: FGF19, sorafenib, copy number gain, hepatocellular carcinoma
Received: November 04, 2015 Accepted: May 17, 2016 Published: June 15, 2016
The multi-kinase inhibitor sorafenib is clinically approved for the treatment of patients with advanced hepatocellular carcinoma (HCC). We previously reported that fibroblast growth factor 3 and 4 (FGF3/FGF4) amplification is a predictor of a response to sorafenib. This study aims to analyze the relationship between FGF-FGF receptor (FGFR) genetic alterations and the response to sorafenib. Formalin-fixed, paraffin-embedded tissue specimens from HCC patients who had achieved a complete response (CR, N=6) or non-CR (N=39) to sorafenib were collected and were examined for FGF-FGFR gene alterations using next generation sequencing and copy number assay. FGFR mutations were detected in 5 of 45 (11.1%) cases. There was no significant association between FGFR mutation status and the response to sorafenib. We detected no increase in the FGF3/FGF4 copy number in CR cases. An FGF19 copy number gain was detected more frequently among CR cases (2/6, 33.3%) than among non-CR cases (2/39, 5.1%) (P = 0.024, Chi-squared test). In conclusion, a copy number gain for FGF19 may be a predictor of a response to sorafenib, in addition to FGF3/FGF4 amplification.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.